85po

中国工程院院士，主任医师、教授、博士生导师。现任东部战区总医院肾脏病科主任，国家肾脏疾病临床医学研究中心主任，江苏省肾脏疾病临床医学研究中心主任，全军肾脏病重点实验室主任。中华医学会理事会常务理事，中华医学会肾脏病学分会第九届主任委员，江苏省医学会副会长，江苏省科学技术协会副主席。曾任85po 、浙江大学85po 院长。国际肾脏病学会（ISN）常务理事，国际肾脏病全球促进委员会KDIGO常务理事。《肾脏病与透析肾移植杂志》主编，《Kidney Disease》创始主编。

获国家科技进步二等奖4项，省部级科技进步奖及自然科学一等奖9项。研究成果先后发表在Nature、Nature Medicine、Cell子刊、Lancet子刊、JAMA子刊、JCI、JASN及Kidney Int等国际顶尖杂志，入选全球前2%顶尖科学家榜，终身影响力榜单。荣获全国优秀科技工作者、全国“巾帼建功”标兵、全国三八红旗手、中国医学科学家奖、中国科协青年科技奖、中国科协“求是”杰出青年工程奖、中国工程院光华工程奖、全军优秀共产党员以及全军重大贡献奖等荣誉称号。

1.       国际肾脏病学会（ISN）  常务理事

2.       国际肾脏病全球促进委员会KDIGO   常务理事

3.       美国布朗（Brown）大学客座教授

4.       中华医学会理事会   常务理事

5.       中华医学会肾脏病学分会第九届   主任委员

6.       国家“973”计划项目    首席科学家

7.       国家科技支撑计划项目    首席科学家

8.       国家“精准医学”重点研发计划项目  首席科学家

9.       江苏省医学会   副会长

10.  江苏省科学技术协会  副主席

1.       Wang Q, Zhu H, Sun X, Zhihong Liu. Loss-of-function mutations in PLD4 lead to systemic lupus erythematosus. Nature. 2025;647(8089):498-505.(IF:48.5)

2.       Feng J, Huo D, Hong R, Zhihong Liu. Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial. Nat Med. 2025;31(11):3725-3736. (IF:50.0)

3.       Zhihong Liu. Nephrology in china. Nat Rev Nephrol. 2013;9(9):523-528. doi:10.1038/nrneph.2013.146 .(IF:39.8)

4.       Cheng C, Wang G, Zhu Y, Zhihong Liu. Multiplexed bulk and single-cell RNA-seq hybrid enables cost-efficient disease modeling with chimeric organoids. Nat Commun. 2024;15(1):3946. Published 2024 May 10. (IF:15.7)

5.       You N, Liu C, Gu Y, Zhihong Liu. SpliceTransformer predicts tissue-specific splicing linked to human diseases. Nat Commun. 2024;15(1):9129. Published 2024 Oct 23. (IF:15.7)

6.       Zhu Y, Zhang M, Wang W,Zhihong Liu. Polynucleotide phosphorylase protects against renal tubular injury via blocking mt-dsRNA-PKR-eIF2α axis. Nat Commun. 2023;14(1):1223. Published 2023 Mar 3. (IF:15.7)

7.       Wang Q, Zhang Y, Zhang B,Zhihong Liu. Single-cell chromatin accessibility landscape in kidney identifies additional cell-of-origin in heterogenous papillary renal cell carcinoma. Nat Commun. 2022;13(1):31. Published 2022 Jan 10. (IF:15.7)

8.       Zhai X, Mao C, Shen Q,Zhihong Liu. Molecular insights into the distinct signaling duration for the peptide-induced PTH1R activation. Nat Commun. 2022;13(1):6276. Published 2022 Oct 21. (IF:15.7)

9.       Zhihong Liu, Zhang H, Zhihong Liu. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015;162(1):18-26. (IF:15.2)

10.  Yang W, Jia M, Zhou F, Zhihong Liu. Renal tubular VMP1 protects against acute kidney injury via modulating autophagy and autophagy-independent pathway. Autophagy. Published online July 27, 2025. (IF:14.3)

11.  Guo Z, Gao S, Wang Z, Zhihong Liu. Engineered RGD-Treg-Exos Targeted Delivery of miR-218-5p to Activate Mitophagy and Attenuate Podocyte Injury in Diabetic Kidney Disease. Adv Sci (Weinh). 2025;12(37):e12034. (IF:14.1)

12.  Wang G, Wu H, Zhai X, Zhihong Liu. Kidney Organoid Modeling of WT1 Mutations Reveals Key Regulatory Paths Underlying Podocyte Development. Adv Sci (Weinh). 2024;11(29):e2308556. (IF:14.1)

13.  Xu X, Qu S, Zhang C, Zhihong Liu. CD8 T Cell-Derived Exosomal miR-186-5p Elicits Renal Inflammation via Activating Tubular TLR7/8 Signal Axis. Adv Sci (Weinh). 2023;10(25):e2301492. (IF:14.1)

14.  Wu J, Zheng C, Wang X, Zhihong Liu. MicroRNA-30 family members regulate calcium/calcineurin signaling in podocytes. J Clin Invest. 2015;125(11):4091-4106. (IF:13.6)

15.  Yang R, Hou Q, Chen R, Ma Z, Jiang S, Zhihong Liu. Protein UHRF1-mediated dual dysregulation of molecular chaperone GRP78 induces endoplasmic reticulum stress and aggravates diabetic nephropathy. Kidney Int. 2025;108(5):883-900. (IF:12.6)

16.  Guo Z, Gao S, Xu F, Zhihong Liu. RGD-HSA-TAC nanoparticles targeted delivery of tacrolimus and attenuation of podocyte injury in diabetic kidney disease. J Nanobiotechnology. 2025;23(1):81. Published 2025 Feb 4. (IF:12.6)

17.  Fu J, Wang Z, Lee K, Zhihong Liu. Transcriptomic analysis uncovers novel synergistic mechanisms in combination therapy for lupus nephritis. Kidney Int. 2018;93(2):416-429. (IF:12.6)

18.  Fu J, Wei C, Zhang W, Zhihong Liu. Gene expression profiles of glomerular endothelial cells support their role in the glomerulopathy of diabetic mice. Kidney Int. 2018;94(2):326-345.  (IF:12.6)

19.  Bao H, Chen H, Zhu X,Zhihong Liu. MiR-223 downregulation promotes glomerular endothelial cell activation by upregulating importin α4 and α5 in IgA nephropathy. Kidney Int. 2014;85(3):624-635. doi:10.1038/ki.2013.469. (IF:12.6)

20.  Lin W, Zhang Q, Liu L, Yin S, Zhihong Liu. Klotho restoration via acetylation of Peroxisome Proliferation-Activated Receptor γ reduces the progression of chronic kidney disease. Kidney Int. 2017;92(3):669-679. (IF:12.6)

21.  Chen Y, Zhang M, Jia R,Zhihong Liu. Podocyte SIRPα reduction in diabetic nephropathy aggravates podocyte injury by promoting pyruvate kinase M2 nuclear translocation. Redox Biol. 2024;78:103439. (IF:11.9)

22.  Yang W, Zhang M, Li J, Zhihong Liu. YTHDF1 mitigates acute kidney injury via safeguarding m⁶A-methylated mRNAs in stress granules of renal tubules. Redox Biol. 2023;67:102921. doi:10.1016/j.redox.2023.102921(IF:11.9)

23.  Zhao Y, Zheng Z, Jin X, Zhihong Liu. Aurora kinase B inhibitor AZD1152: repurposing for treatment of lupus nephritis driven by the results of clinical trials. EBioMedicine. 2025;112:105553. (IF:10.8)

24.  Chen T, Xia E, Chen T, Zhihong Liu. Identification and external validation of IgA nephropathy patients benefiting from immunosuppression therapy. EBioMedicine. 2020;52:102657. (IF:10.8)

25.  Jiang S, Jia H, Hou Q,Zhihong Liu. Multimodal analysis stratifies genetic susceptibility and reveals the pathogenic mechanism of kidney injury in diabetic nephropathy. Cell Rep Med. 2025;6(8):102249. (IF:10.6)

26.  Hu S, Han R, Chen L, Zhihong Liu. Upregulated LRRC55 promotes BK channel activation and aggravates cell injury in podocytes. J Exp Med. 2021;218(3):e20192373. (IF:10.6)

27.   Zhang H, Li G, Yu X,Zhihong Liu. Progression of Vascular Calcification and Clinical Outcomes in Patients Receiving Maintenance Dialysis. JAMA Netw Open. 2023;6(5):e2310909. Published 2023 May 1. (IF:9.7)

28.  Zheng Z, Zhang H, Peng X, Zhihong Liu. Effect of Tacrolimus vs Intravenous Cyclophosphamide on Complete or Partial Response in Patients With Lupus Nephritis: A Randomized Clinical Trial. JAMA Netw Open. 2022;5(3):e224492. Published 2022 Mar 1. (IF:9.7)

29.  Wang H, Lv D, Jiang S, Zhihong Liu. Complement induces podocyte pyroptosis in membranous nephropathy by mediating mitochondrial dysfunction. Cell Death Dis. 2022;13(3):281. Published 2022 Mar 29. (IF:9.6)

30.  Lang Y, Zhao Y, Zheng C, Zhihong Liu. MiR-30 family prevents uPAR-ITGB3 signaling activation through calcineurin-NFATC pathway to protect podocytes. Cell Death Dis. 2019;10(6):401. Published 2019 May 24. (IF:9.6)

31.  Wu J, Zheng C, Fan Y, Zhihong Liu. Downregulation of microRNA-30 facilitates podocyte injury and is prevented by glucocorticoids. J Am Soc Nephrol. 2014;25(1):92-104. doi:10.1681/ASN.2012111101. (IF:9.4)

32.  Peng J, Wang Y, Han X,Zhihong Liu. Clinical Implications of a New DDX58 Pathogenic Variant That Causes Lupus Nephritis due to RIG-I Hyperactivation. J Am Soc Nephrol. 2023;34(2):258-272.(IF:9.4)

33.  Yang J, Zhang D, Motojima M, Zhihong Liu. Super-Enhancer-Associated Transcription Factors Maintain Transcriptional Regulation in Mature Podocytes. J Am Soc Nephrol. 2021;32(6):1323-1337. (IF:9.4)

34.  Zhang H, Zhihong Liu. Multitarget Therapy for Maintenance Treatment of Lupus Nephritis. J Am Soc Nephrol. 2017;28(12):3671-3678. (IF:9.4)

35.  Le WB, Shi JS, Zhang T, Zhihong Liu. HLA-DRB1*15:01 and HLA-DRB3*02:02 in PLA2R-Related Membranous Nephropathy. J Am Soc Nephrol. 2017;28(5):1642-1650. (IF:9.4)

36.  Qin HZ, Zhang MC, Le WB, Zhihong Liu. Combined Assessment of Phospholipase A2 Receptor Autoantibodies and Glomerular Deposits in Membranous Nephropathy. J Am Soc Nephrol. 2016;27(10):3195-3203. (IF:9.4)

37.  Meng J, Li L, Zhao Y, Zhihong Liu. MicroRNA-196a/b Mitigate Renal Fibrosis by Targeting TGF-β Receptor 2. J Am Soc Nephrol. 2016;27(10):3006-3021. (IF:9.4)

38.  Fu J, Wei C, Lee K, Zhihong Liu. Comparison of Glomerular and Podocyte mRNA Profiles in Streptozotocin-Induced Diabetes. J Am Soc Nephrol. 2016;27(4):1006-1014. (IF:9.4)

39.  Li L, Zhang T, Diao W, Zhihong Liu. Role of Myeloid-Derived Suppressor Cells in Glucocorticoid-Mediated Amelioration of FSGS. J Am Soc Nephrol. 2015;26(9):2183-2197. (IF:9.4)

40.  Huang X, Wang Q, Chen W,Zhihong Liu. Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial. BMC Med. 2014;12:2. Published 2014 Jan 6. (IF:8.3)

41.  Chen T, Li X, Li Y, Zhihong Liu. Prediction and Risk Stratification of Kidney Outcomes in IgA Nephropathy. Am J Kidney Dis. 2019;74(3):300-309.  (IF:8.2)

42.  Hou JH, Le WB, Chen N, Zhihong Liu. Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial. Am J Kidney Dis. 2017;69(6):788-795. (IF:8.2)

43.  Zhang C, Zhang W, Chen HM, Zhihong Liu. Plasma microRNA-186 and proteinuria in focal segmental glomerulosclerosis. Am J Kidney Dis. 2015;65(2):223-232. (IF:8.2)

44.  Pan Y, Jiang S, Hou Q, Zhihong Liu. Dissection of Glomerular Transcriptional Profile in Patients With Diabetic Nephropathy: SRGAP2a Protects Podocyte Structure and Function. Diabetes. 2018;67(4):717-730. (IF:7.5)

45.  Chen T, Chen T, Xu W, Zhihong Liu. Development and External Validation of a Multidimensional Deep Learning Model to Dynamically Predict Kidney Outcomes in IgA Nephropathy. Clin J Am Soc Nephrol. 2024;19(7):898-907.(IF:7.1)

46.  Sun Y, Xu L, Li Y, Zhihong Liu. Mitophagy defect mediates the aging-associated hallmarks in Hutchinson-Gilford progeria syndrome. Aging Cell. 2024;23(6):e14143. (IF:7.1)

47.  Zhang C, Han X, Jin Y, Zhihong Liu. Pathogenic Gene Spectrum and Clinical Implication in Chinese Patients with Lupus Nephritis. Clin J Am Soc Nephrol. 2023;18(7):869-880. (IF:7.1)

48.  Wang W, Yu Y, Wen J, Zhihong Liu. Combination of Functional Magnetic Resonance Imaging and Histopathologic Analysis to Evaluate Interstitial Fibrosis in Kidney Allografts. Clin J Am Soc Nephrol. 2019;14(9):1372-1380. (IF:7.1)

49.  Wang H, Zheng C, Lu Y, Zhihong Liu. Urinary Fibrinogen as a Predictor of Progression of CKD. Clin J Am Soc Nephrol. 2017;12(12):1922-1929. (IF:7.1)

50.  Zhang W, Zhang C, Chen H, Zhihong Liu. Evaluation of microRNAs miR-196a, miR-30a-5P, and miR-490 as biomarkers of disease activity among patients with FSGS. Clin J Am Soc Nephrol. 2014;9(9):1545-1552. (IF:7.1)

51.  Li F, Zheng C, Zhong Y, Zhihong Liu. Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS. Clin J Am Soc Nephrol. 2014;9(11):1903-1911. (IF:7.1)

52.  Zeng M, Di H, Ding J, Zhihong Liu. A Prediction Model of Disease Progression in X-Linked Alport syndrome Based on Clinical Characteristics and Genetic Variants. Kidney Int Rep. 2025;10(6):2024-2034. Published 2025 Mar 10.(IF:5.7)

53.  Zhang C, Liang D, Zhihong Liu. Primary immunodeficiency as a cause of immune-mediated kidney diseases. Nephrol Dial Transplant. 2024;39(11):1772-1784. (IF:5.6)

54.  Zeng M, Di H, Liang J, Zhihong Liu.. Effectiveness of renin-angiotensin-aldosterone system blockers in patients with Alport syndrome: a systematic review and meta-analysis. Nephrol Dial Transplant. 2023;38(11):2485-2493. (IF:5.6)

55.  Di H, Zhang J, Gao E, Zhihong Liu. Dissecting the genotype-phenotype correlation of COL4A5 gene mutation and its response to renin-angiotensin-aldosterone system blockers in Chinese male patients with Alport syndrome. Nephrol Dial Transplant. 2022;37(12):2487-2495. (IF:5.6)

56.  Li S, Liu Y, He Y, Zhihong Liu. Podocytes present antigen to activate specific T cell immune responses in inflammatory renal disease. J Pathol. 2020;252(2):165-177. (IF:5.2)

57.  Zeng C, Nan Y, Xu F, Zhihong Liu. Identification of glomerular lesions and intrinsic glomerular cell types in kidney diseases via deep learning. J Pathol. 2020;252(1):53-64. (IF:5.2)

58.  Xu Y, Xiang Z, E W, Zhihong Liu. Single-cell transcriptomes reveal a molecular link between diabetic kidney and retinal lesions. Commun Biol. 2023;6(1):912. Published 2023 Sep 5. (IF:5.1)

59.  Lu J, Liu X, Jiang S, Zhihong Liu. Body Mass Index and Risk of Diabetic Nephropathy: A Mendelian Randomization Study. J Clin Endocrinol Metab. 2022;107(6):1599-1608. (IF:5.1)

60.  Wang H, Duan A, Zhang J, Zhihong Liu. Glucocorticoid receptor wields chromatin interactions to tune transcription for cytoskeleton stabilization in podocytes. Commun Biol. 2021;4(1):675. Published 2021 Jun 3. (IF:5.1)

1. 常见肾小球疾病发病机制及其早期诊断

国家“973” 项目（首席）（2012CB517600），3800万，项目负责人

2. 系统性红斑狼疮发病机制及诊疗新策略研究

国家自然科学基金专项项目（32141004），2000万，项目负责人

3. 慢性肾脏疾病新型治疗方法临床试验和新型诊疗技术的研究

国家科技支撑计划课题（2013BAI09B04），600万，项目负责人

4.狼疮性肾炎及血管炎肾损害的诊断与治疗

国家科技支撑计划课题（2011BAI10B04），520万，项目负责人

5.基于多组学图谱的免疫性肾小球疾病分子分型研究

国家“精准医学”重点研发计划项目（2016YFC0904100），320万，项目负责人

6.常见肾脏疾病的发病机制及早期诊断

教育部“创新团队发展计划”（IRT1253），300万，项目负责人

7.足细胞损伤与修复机制

国家自然科学基金重大国际合作（81320108007），280万，项目负责人

8.IgA肾病发病机制及其病理学基础的研究

国家自然科学基金重大国际合作（81020108016），200万，项目负责人

9.间充质干细胞治疗狼疮肾炎的关键技术及分子机制研究

江苏省基础研究计划重点项目（BK20243061)，500万，项目负责人

1.       2021.09 获国家级科学技术进步二等奖：

肾小球肾炎诊治策略和关键技术的创新与应用

2.       1999.12获国家级科学技术进步二等奖：

基因多态性与我国肾脏疾病临床表型及预后的研究

3.       1993.12获国家级科学技术进步二等奖：

大黄延缓慢性肾功能衰竭的机理及疗效 

4.       1992.11获国家级科学技术进步二等奖：

我国IgA肾病免疫发病机理与诊断及治疗的研究

5.       2010.01 获教育部科技进步一等奖：

狼疮性肾炎治疗的研究和创新

6.       2003.01 获教育部自然科学一等奖：

糖尿病肾病分子病因学及其防治的研究

7.       2017.01 获中华医学科技奖一等奖：

狼疮性肾炎和IgA肾病的诊断和治疗新技术

8.       2015.01 获军队医疗成果一等奖：

肾脏疾病临床诊断和治疗新技术

9.       2017.02 获江苏省科技进步奖一等奖：

足细胞损伤机制及临床转化研究

10.  2016.12 获江苏省医学科技奖一等奖：